Prevalence of Haemarthrosis and Clinical Impact on The Musculoskeletal System in People With Haemophilia in The United Kingdom; Evaluation of UK National Haemophilia Database and Haemtrack Patient Reported Data.

Introduction; Severe haemophilia is a rare x-linked recessive genetic disorder characterised by bleeding into soft tissue and joints. Haemarthrosis is the most common bleeding manifestation in haemophilia, leading to haemarthropathy. The ankle joint has been reported as the most common site of bleeding, but it is unclear whether the ankle is most affected in terms of joint health status. Aims; To determine the prevalence of joint bleeding and musculoskeletal health status at an individual joint level of children and adults with severe haemophilia A and B without a current inhibitor.Methods; Application was made to the National Haemophilia Database (NHD) with a request for the following; Haemtrack patient reported treatment record and Haemophilia Joint Health Scores (HJHS) in children (<18y) and adults (≥18y) with severe haemophilia A (HA) and B (HB) (FVIII/FIX, <0.01 iu/ml) without a current inhibitor. Data were collated and reported for 1st January to 31st December 2018.Results; 2238 cases were identified, of which 273 were Haemtrack compliant with contemporaneous HJHS. The median (IQR) age of children was 10 (6-13) and adults 40 (29-50) years. Haemarthrosis prevalence in HA/HB children was 33% and 47%, respectively and 60% and 42%, respectively, in adults. The most common haemarthrosis site in children was the knee in HA and ankle in HB. In adults, the incidence of haemarthrosis at the ankles and elbows was equal. Median (IQR) total HJHS in HA/HB children were 0 (0;0). In adults with HA/HB, HJHS were 18 (6; 31) and 11 (5; 24), respectively. In adults with HA/HB, mean (SD) ankle HJHS of 3.8 (4.1) and median 4.0 (0.0; 8.0) were higher than the knee (mean 2.9 (4.1) and median 1.0 (0.0; 5.0) and elbow (mean 3.3 (4.1) and median 1.0 (0.0; 7.0) joints.Conclusion; During 2018, NHD prevalence data of haemarthrosis indicate only two-thirds of children and one-third of adults from a UK cohort compliant with prophylaxis were bleed free. HJHS of zero in children suggests joint health status is either unaffected during childhood or undetected by HJHS. In adults, higher HJHS are reported for the ankles indicating worse joint health.

[1]  P. Chowdary Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges. , 2019, Thrombosis research.

[2]  M. Ragni,et al.  Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  G. Dolan,et al.  Achieving the unimaginable: Health equity in haemophilia , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Abad,et al.  Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1 , 2019, Research and practice in thrombosis and haemostasis.

[5]  M. Scott,et al.  Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  G. Castaman,et al.  Hemophilia A and B: molecular and clinical similarities and differences , 2019, Haematologica.

[7]  L. V. van Vulpen,et al.  Joint disease in haemophilia: Pathophysiology, pain and imaging , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  E. Rodríguez‐Merchán Management of Hemophilic Arthropathy of the Ankle. , 2017, Cardiovascular & hematological disorders drug targets.

[9]  G. Dolan,et al.  The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  S. Frostick,et al.  Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Oldenburg,et al.  European retrospective study of real‐life haemophilia treatment , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  B. Bartels,et al.  Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  F. Sofi,et al.  Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A , 2015, Haematologica.

[14]  J. Oldenburg Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. , 2015, Blood.

[15]  A. Gringeri,et al.  The burden of bleeding in haemophilia: is one bleed too many? , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  P. Mannucci,et al.  Is haemophilia B less severe than haemophilia A? , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  M. Skinner WFH: Closing the global gap – achieving optimal care , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[20]  M. Clerici,et al.  Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile , 2010, Journal of thrombosis and haemostasis : JTH.

[21]  M. Morfini,et al.  Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.

[22]  G. Dolan,et al.  Changing patterns of bleeding in patients with severe haemophilia A , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  K. Mulder,et al.  Orthopaedic management of haemophilia arthropathy of the ankle , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[25]  B. Feldman,et al.  Hemophilia joint health score reliability study , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  F. Lafeber,et al.  Pathogenesis of haemophilic arthropathy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  L. Valentino,et al.  Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. , 2004, Blood.

[28]  K. Pasi,et al.  Haemophilias A and B , 2003, The Lancet.

[29]  J. Bijlsma,et al.  Blood-induced joint damage: longterm effects in vitro and in vivo. , 2003, The Journal of rheumatology.

[30]  J. Bijlsma,et al.  Blood-induced joint damage: a canine in vivo study. , 1999, Arthritis and rheumatism.

[31]  R. G. Macfarlane,et al.  Haemophilia and Related Conditions: A Survey of 187 Cases , 1958, British journal of haematology.

[32]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.